Drugs / Collagen Matrix
Collagen Matrix
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial · 1 missed | ||||||
| Phase 4 | NCT02818855 | Mar 2014 → Oct 2015 | gingival recession | University of Sao Paulo | Completed | Missed primary |
| Phase not applicable1 trial | ||||||
| — | NCT06065774 | Jul 2022 → Apr 2024 | gingival recession | Mansoura University | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-05-08 | Geistlich Pharma AG | Regulatory Innovative skin graft alternative for face, head and neck wounds geistlich.com ↗
Geistlich has received this approval for the expanded anatomical placement of Geistlich Mucograft® in accordance with the European Medical Device Regulation (MDR). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-05-08 | Geistlich Pharma AG | Innovative skin graft alternative for face, head and neck wounds geistlich.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | collagen matrix | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06065774 ↗ |
| Known as | Mucoderm | “Mucoderm or porcine-derived collagen matrix has been used in many studies as an alternative to connective tissue graft CTG as a soft tissue grafting material for volume...” NCT06065774 ↗ |
| Known as | porcine-derived collagen matrix | “Mucoderm or porcine-derived collagen matrix has been used in many studies as an alternative to connective tissue graft CTG as a soft tissue grafting material for volume...” NCT06065774 ↗ |
| Modality | Protein / enzyme biologic | “porcine-derived collagen matrix” NCT06065774 ↗ |